Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Mechanisms, Pharmacology, and Therapeutic Applications in Type 2 Diabetes Mellitus and Obesity Management

Abstract

Background: The global burden of type 2 diabetes mellitus (T2DM) and obesity has reached epidemic proportions, demanding therapeutic strategies that go beyond simple glycemic control. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the metabolic disease treatment landscape over the past two decades by offering simultaneous benefits on blood glucose regulation and body weight reduction.
Objective: This review comprehensively evaluates the pharmacology, pharmacokinetics, clinical efficacy, safety profile, and emerging applications of GLP-1 receptor agonists in T2DM and obesity, with special emphasis on their cardiovascular, renal, and hepatic benefits.
Methods: A systematic review of published clinical trials, meta-analyses, and pharmacological studies was conducted using PubMed, Scopus, and Google Scholar databases. Major cardiovascular outcome trials including LEADER, SUSTAIN-6, REWIND, and PIONEER-6 were critically analyzed.
Results: GLP-1 RAs consistently reduce HbA1c by 0.8–1.5%, promote weight loss of 5–15% of body weight, lower systolic blood pressure, improve lipid profiles, and reduce major adverse cardiovascular events by 12–14% in high-risk populations. Long-acting agents demonstrate superior overall glycemic control and patient compliance, while short-acting agents more effectively attenuate postprandial glucose excursions.
Conclusion: GLP-1 receptor agonists represent a paradigm shift in the management of T2DM and obesity, with benefits extending well beyond glycemic control. Despite limitations including cost and injectable route of administration, their comprehensive metabolic and cardioprotective effects make them indispensable in modern pharmacotherapy.

Keywords